

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent No. 7,053,086 B2
Issue Date: May 30, 2006

Application Serial No.: 10/648,810
Filed: August 27, 2003

Confirmation No.: 3943

Inventors: Peng Cho Tang, et al.

For: 4-HETEROARYL-3-
HETEROARYLIDENYL-2-
INDOLINONES AND THEIR USE AS
PROTEIN KINASE INHIBITORS

Group Art Unit: 1623

Examiner: Paul V. Ward

Attorney Docket No.: PC23537B

Attention: Certificate of Correction Branch
Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION OF OFFICE MISTAKE PURSUANT TO 35
U.S.C. § 254 and 37 CFR § 1.322

Sir:

Pursuant to 35 U.S.C. § 254 and 37 CFR § 1.322, Agent for Applicants respectfully requests issuance of a Certificate of Correction to correct several mistakes in the claims of U.S. Patent No. 7,053,086 B2 incurred through the fault of the Office.

In Claim 1 please makes the following corrections:

Please change $-(CH^2)_n C(O)OR^{26}$ at column 110, line 31 to $-(CH_2)_n C(O)OR^{26}$.

Please change $-O(CH^2)_n NR^{26}R^{29}$ at column 110, line 48 to $-O(CH_2)_n NR^{26}R^{29}$.

Please change $-O(CH^2)_n NR^{26}R^{29}$ at column 110, line 56 to $-O(CH_2)_n NR^{26}R^{29}$.

Please change $-O(CH^2)_n NR^{26}R^{29}$ at column 110, line 65 to $-O(CH_2)_n NR^{26}R^{29}$.

Please change $-(CH^2)_n NR^{26}R^{29}$ at column 110, line 66 to $-(CH_2)_n NR^{26}R^{29}$.

Evidence that the mistakes noted above were the fault of the Office is clearly disclosed in the prosecution record. Applicants submit a dated stamped copy of the amendment containing the issued claims. All of the substituents listed above are correctly written in the amendment.

Respectfully submitted,

Date: July 27, 2006

/Vincent P. Liptak/
Vincent P. Liptak
Agent for Applicants
Registration No. 53,225

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 622-7908
Fax: (858) 678-8233